The emergence of COVID-19 in Indonesia: analysis of predictors of infection and mortality using independent and clustered data approaches

Erlina Burhan^{1,2}¶, Ari Fahrial Syam³, Ahmad Jabir Rahyussalim⁴, Prasenohadi^{1,2}, Navy G Lolong Wulung², Agus Dwi Susanto^{1,2}, I Gede Ketut Sajinadiyasa⁵, Dewi Puspitorini⁶, Dewi Lestari⁷, Indah Suci Widyahening⁸, Vivi Setiawaty⁹, Dwiana Ocviyanti¹⁰, Kartika Qonita Putri¹¹, Aswin Guntara¹¹, Davrina Rianda¹², Anuraj H Shankar^{13,14}¶, Rina Agustina^{12,15}¶*

Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

¹ Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia

² Persahabatan General Hospital, Jakarta, Indonesia

³ Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

⁴ Department of Orthopedic and Traumatology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

⁵ Sanglah General Hospital, Bali, Indonesia

⁶ Gatot Soebroto Central Army Hospital, Jakarta, Indonesia

⁷ Raden Mattaher District Hospital, Jambi, Indonesia

⁸ Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

⁹ Center for Research and Development for Biomedical and Basic Health Technology, National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia, Jakarta, Indonesia

¹⁰ Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Indonesia,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. It Medical Study Program, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

¹² Human Nutrition Research Center, Indonesian Medical Education and Research Center,

Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

¹³ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,

University of Oxford, Oxford, United Kingdom

¹⁴ Eijkman-Oxford Clinical Research Unit, Eijkman Institute for Molecular Biology, Jakarta,

Indonesia

¹⁵ Department of Nutrition, Faculty of Medicine, Universitas Indonesia, Dr. Cipto

Mangunkusumo General Hospital, Jakarta, Indonesia

*Corresponding Author:

E-mail: r.agustina@ui.ac.id

These authors contributed equally to this manuscript

Running title: The emergence of COVID-19 in Indonesia

Abstract

Background: Analyses of correlates of SARS-CoV-2 infection or mortality have usually assessed individual predictors. This study aimed to determine if patterns of combined predictors may better identify risk of infection and mortality

Methods: For the period of March 2nd to 10th 2020, the first 9 days of the COVID-19 pandemic in Indonesia, we selected all 18 confirmed cases, of which 6 died, and all 60 suspected cases, of which 1 died; and 28 putatively negative patients with pneumonia and no travel history. We recorded data for travel, contact history, symptoms, haematology, comorbidities, and chest x-ray. Hierarchical cluster analyses (HCA) and principal component analyses (PCA) identified cluster and covariance patterns for symptoms or haematology which were analysed with other predictors of infection or mortality using logistic regression.

Results: For univariate analyses, no significant association with infection was seen for fever, cough, dyspnoea, headache, runny nose, sore throat, gastrointestinal complaints (GIC), or haematology. A PCA symptom component for fever, cough, and GIC tended to increase risk of infection (OR 3.41; 95% CI 1.06-14; p=0.06), and a haematology component with elevated monocytes decreased risk (OR 0.26; 0.07-0.79; 0.027). Multivariate analysis revealed that an HCA cluster of 3-5 symptoms, typically fever, cough, headache, runny nose, sore throat but little dyspnoea and no GIC tended to reduce risk (aOR 0.048; <0.001–0.52; 0.056). In univariate analyses for death, an HCA cluster of cough, fever and dyspnoea had increased risk (OR 5.75; 1.06 - 31.3, 0.043), but no other individual predictor, cluster or component was associated. Other significant predictors of infection were age \geq 45, international travel, contact with COVID-19 patient, and pneumonia. Diabetes and history of contact were associated with higher mortality.

Conclusions: Cluster groups and co-variance patterns may be stronger correlates of SARS-CoV-2 infection than individual predictors. Comorbidities may warrant careful attention as would COVID-19 exposure levels.

Keywords: Coronavirus, SARS-CoV-2, COVID-19, hierarchical cluster analysis, Indonesia, principal component analysis

Introduction

The coronavirus SARS-CoV-2 is a deadly respiratory pathogen first reported in Wuhan City, Hubei Province of China in early 2020, and rapidly spread globally. On 11 March 2020, the World Health Organization declared a pandemic(1), and by 2 May 2020 the number of confirmed cases worldwide reached nearly 3.3 millions with more than 230,000 deaths, and a global case fatality rate of 7.04%.(2) Indonesia, a large archipelago country in South-east Asia with a population of 260 million, did not report a confirmed COVID-19 case until 2 March 2020, several weeks after a total of 217 cases had been reported from neighboring countries of Singapore, Malaysia, Thailand and Australia. This raised concerns from groups both inside and outside the country regarding diagnostic and reporting practice. However, by 2 May 2020 the number of confirmed cases were 10,551, with 800 deaths, yielding a case fatality rate of 7.58%, amongst the highest in the world.(2) Again, this raised concerns about both the diagnostic capacity and care of cases.

The availability of routine data for case history, symptoms, haematology and radiology presents an opportunity to define presentation patterns predictive for COVID-19. Knowledge of anomalous risk patterns may be especially useful at the early phase of the epidemic in new locations when high throughput molecular testing is not yet available. Analyses of syndromic and haematology data in some studies showed the most common symptoms of COVID-19 were fever, cough, and lymphocytopenia. Patients may also be asymptomatic yet with abnormal findings from lung imaging.(3) Previous analyses typically examined each symptom, exposure or hematological characteristic individually or as separate predictors of SARS-CoV-2 infection, pathogenicity, or mortality. Few studies have examined clusters or co-variance patterns of symptoms, exposures, haematological data, or combinations thereof, and their associations with outcomes.

We therefore analysed routine clinical data and patient history from all hospital admissions during the first nine days of the epidemic in Indonesia who were confirmed by

real time polymerase chain reaction (RT-PCR) as COVID-19 cases, and all suspect but virus negative cases, and other lung infection cases presumed negative for the virus. We applied hierarchical cluster analysis (HCA) and principal components analysis (PCA) to discern specific clusters or co-variance patterns of syndromic and haemotological data, and analysed these along with radiological features and patient history for associations with SARS-CoV-2 infection or death using univariate and multivariate logistic regression. These analytic approaches may prove useful for more rapid recognition of emergent COVID-19 cases, thereby hastening treatment, and enhancing survival.

Materials and methods

Study setting

This was a retrospective cohort study of patients from four collaborating hospitals in Jakarta, Bali and Jambi provinces which had reported suspected and confirmed case of COVID-19 to the Ministry of Health. We collected data from confirmed, suspected and lung infection cases admitted from March 2nd to 10th 2020, the first nine days of cases in Indonesia. Ethical approval was obtained from the Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, with approval number 20030331. After consideration of ethical issues, logistics and urgency of this work, the Committee waived the requirement for written individual informed consent and approved the sharing of anonymized data.

Patients identification

As per hospital protocols, patients admitted with respiratory infections had been registered as potential COVID-19 cases and been classified as under-supervision or monitored. Under-supervision had included patients with clinical symptoms of fever (>38 °C)

or history of fever, runny nose, sore throat, and pneumonia-like symptoms such as cough, dyspnoea, sweating, sharp chest pain worsened by breathing deeply, or cough with a history of travel to a COVID-19 affected country in the last 14 days, or having contact with a person with acute upper respiratory tract infection. Monitored had been defined as upper respiratory symptoms without pneumonia-like symptoms, plus travel history to an affected country within 14 days.

A confirmed COVID-19 case was an under-supervision or monitored patient with a positive SARS-CoV-2 test by RT-PCR for naso-oropharyngeal swab, sputum, or bronchoalveolar lavage (18 patients); a suspected case was a patient twice-confirmed negative by RT-PCR test (47 patients) or not assessed (13 patients); and formal classification required the case had been reported to the Ministry of Health of the Republic Indonesia. For comparison, we selected patients with community acquired pneumonia who were admitted between January 1st to March 10th 2020 and reported no history of international travel. A total of 18 confirmed COVID-19 patients, 60 suspected patients, and 28 lung patients were identified.

Data collection

Study physicians reviewed medical records of hospitalized patients, and in accord with World Health Organization diagnostic guidelines, and hospital procedures, data were extracted for demographics, nationality, travel history, clinical signs, radiological features, and haemotology, including haemoglobin and hematocrit, and counts for thrombocytes, total leucocytes, monocytes, lymphocytes, basophils, neutrophils, and eosinophils. Patients with symptoms of acute respiratory tract infection or travel history from COVID-19-affected countries within the last 14 days had been assessed in the emergency room or out-patient clinic(4), and case history, physical examination and chest x-rays had been done within the hospital. Venous blood samples had been taken for complete white blood cell count. Some

samples were assessed for electrolytes, lactic acid products, C-reactive protein, procalcitonin, and liver as well as renal function tests; these tests were selectively assessed and gaps in data precluded inclusion in this analysis. Chest computed tomography (CT) scan was not reported for any patient.(5)

Naso-oropharyngeal swab, sputum or bronchoalveolar lavage specimens had been sent to the National Institutes for Health Research and Development (NIHRD) laboratory in Jakarta for RT-PCR to assess presence of the virus. Tests were performed after virus inactivation, and RNA was extracted using the QiAmp RNA viral kit based on the instructions and standard laboratory techniques, followed by RT-PCR using SuperScriptTM III Platinum® One-Step Quantitative RT-PCR for the N gene in accord with US CDC protocols.(6)

Statistical analyses

Descriptive statistics for continuous data are presented as the mean and standard deviation (SD) for normally distributed data, and median and interquartile range (IQR) for non-normal data. Normality of haematology data was assessed by the Shapiro-Wilk test and QQ plots and, if needed, data were normalized by log, square root, or cube root transforms, or reflection followed by transform. Normalized data were standardized to a mean of zero and standard deviation of one. Comparisons for differences between groups was by one-way ANOVA or the Kruskal-Wallis test for non-parametric data. Categorical and binary data were expressed as the number and proportion (%) with comparison using the χ^2 test. Univariate logistic regression was used to identify the association of risk factors, or independent variables, such as demography, symptoms, comorbidities, chest x-ray abnormalities, and laboratory assessments, with SARS-CoV-2 infection or death as dependent variables. Multivariate logistic regression with backward selection was used with a cutoff of p<0.15 from univariate regression, and retained variables previously reported to affect the outcomes.

Firth's logistic regression was used to permit calculation of regression coefficients when standard logistic regression failed due to the binary outcome prevalence being very high or very low for a particular risk factor. A two-sided α of <0.05 was considered statistically significant. SPSS V.26.0 and SAS 9.4 were used for all analyses.

PCA was performed to identify composite symptom and laboratory components based on their co-variance constructs. Categorical PCA was used for binary symptom data, and conventional PCA for continuous, normalized, and standardized laboratory data. For laboratory data, missing values were imputed as the mean of each variable. A component was retained following cross validation if eigenvalues were above the cutoffs defined by Horn's parallel analysis. Principal component scores were recoded to tertiles and used as predictors of SARS-CoV-2 infection or death by logistic regression with the lowest tertile as the reference category.

HCA was used to define clusters of association of symptoms and other characteristics. The number of retained clusters were determined as 5 based on the highest adjusted Rand index with a high number of clusters and a high pseudo T2 statistic. Cluster memberships were used as predictors of SARS-CoV-2 infection or death by logistic regression.

Symptoms and hematological data were analysed as separate variables as risk factors for associations with SARS-CoV-2 infection or death using univariate and multivariate logistic regression, and after classification into patterns or clusters of risk factors defined by PCA or HCA, followed by logistic regression.

Results

In Table 1 we summarize patient characteristics, including age, gender, history of international exposure, history of contact, symptoms, haematology, comorbidities, chest x-ray abnormalities, and diagnosis at discharge. A total of 106 subjects comprised of 18 confirmed COVID-19, 60 suspected, and 28 lung infection cases. The mean age of all

subjects was 44.8 ± 18.7 years with 42% being 45-65 years old. The mean age of confirmed cases was 52.6 ± 10.4 years, older than suspected patients who were 35.6 ± 17.3 years, but younger than for lung infection cases who were 59.3 ± 14 . The gender distribution was nearly equal, except in the confirmed case group wherein 66.7% were male. International travel history was found in 50% of confirmed, and 85.0% of suspected cases. Moreover, 50% of confirmed and 16.7% of suspected cases had contact history with COVID-19 patients.

Fever and cough, followed by dyspnoea, were the most frequent symptoms followed by runny nose, sore throat, headache, and gastrointestinal complaints (GIC). Comorbidities were present in nearly half of patients, with combined severe diseases as the most common, followed by pre-existing respiratory disorders and diabetes mellitus. However, there were no pre-existing respiratory disorders in confirmed COVID-19 cases. The two most common disorders of confirmed cases were diabetes (27.8%) and hypertension (27.8%).

Chest x-ray showed pneumonia in 94.4% of confirmed and 53.3% of suspected cases. Among the suspected cases, 25% were within normal limits. Consolidation was less frequently reported in confirmed cases. Haematology did not show lymphopenia or thrombocytopenia in confirmed or suspected cases. However, a lower level of leucocytes was seen in suspected and confirmed cases, whereas leucocytosis was observed more frequently in 85% of the lung infection cases.

Table 1. General characteristics of the study patients by category

Characteristics	All	Non	COVID-19	COVID-19	Survivor	Death
		Suspected	Lung infection	Confirmed		
	n= 106	n = 60	n=28	n = 18	n=99	n=7
Demography						
Age (yr) ^a	44.8 (18.7)	35.6 (17.3)	59.3 (14.0)	52.6 (10.4)	43.5 (18.6)	59.6 (6.29)
Distribution (yr), n (%)						
0-18	8 (7.5)	8 (13.3)	0 (0)	0 (0)	8 (8.0)	0 (0)
19-30	13 (12.3)	11 (18.3)	1 (3.6)	1 (5.6)	13 (13.0)	0 (0)
31-44	29 (27.4)	23 (38.3)	3 (10.7)	3 (16.7)	29 (29.0)	0 (0)
45-65	45 (42.5)	16 (26.7)	16 (57.1)	13 (72.2)	39 (39.0)	7 (100)
> 65	11 (10.4)	2 (3.3)	8 (28.6)	1 (5.6)	11 (11.0)	0 (0)
Male, n (%)	55 (51.9)	29 (48.3)	14 (50.0)	12 (66.7)	51 (51.0)	4 (57.1)
International travel, n (%)	59 (55.7)	51 (85.0)	0 (0)	8 (44.4)	59 (59.6)	1 (14.3)
No	47 (44.3)	9 (15.0)	28 (100)	10 (55.6)	42 (42.0)	6 (85.7)
China	17 (16.0)	17 (28.3)	0 (0)	0 (0)	17 (17.0)	0 (0)
Singapore and/ Malaysia	19 (17.9)	14 (23.3)	0 (0)	5 (27.8)	18 (18.0)	1 (14.3)
Asian countries	17 (16.0)	16 (26.7)	0 (0)	1 (5.6)	17 (17.0)	0 (0)
Other countries	5 (4.7)	4 (6.7)	0 (0)	1 (5.6)	5 (5.0)	0 (0)
Diamond Princess Boat	1 (0.9)	0 (0)	0 (0)	1 (5.6)	1 (1.0)	0 (0)
Contact history, n (%)	19 (17.9)	10 (16.7)	0 (0)	9 (50.0)	14 (14.1)	5 (71.4)
Symptoms b, n (%)						
Fever duration (days) ^a	3 (1 - 5.3)	2 (1 - 3)	3 (3 - 6.5)	10 (7 - 14)	3 (1-5)	3 (6 - 11.5)
Fever	83 (78.3)	48 (80.0)	20 (71.4)	15 (83.3)	78 (78.0)	5 (71.4)
Headache	8 (7.5)	8 (13.3)	0 (0)	0 (0)	8 (8.1)	0 (0)
Runny nose	20 (18.9)	20 (33.3)	0 (0)	0 (0)	20 (20)	0 (0)
Cough	89 (84.0)	48 (80.0)	25 (89.3)	16 (88.9)	83 (83.8)	6 (85.7)
Sore throat	11 (10.4)	11 (18.3)	0 (0)	0(0)	11 (11.0)	0 (0)
Dyspnoea	51 (48.1)	18 (30.0)	24 (85.7)	9 (50.0)	45 (45.5)	6 (85.7)
GIT complaints	5 (4.7)	5 (8.3)	0 (0)	0 (0)	5 (5.1)	0 (0)

Characteristics	All	Non C	OVID-19	COVID-19	Survivor	Death
		Suspected	Lung infection	Confirmed		
	n= 106	n = 60	n=28	n = 18	n=99	n=7
Coexisting disorder, n (%)						
Any	45 (42.5)	10 (16.7)	27 (96.4)	8 (44.4)	41 (41.4)	4 (57.1)
Diabetes	14 (13.2)	2 (3.3)	7 (25)	5 (27.8)	10 (10.0)	4 (57.1)
Hypertension	13 (12.3)	3 (5)	5 (17.9)	5 (27.8)	11 (11.0)	2 (28.6)
Heart disease ^c	8 (7.5)	1 (1.7)	7 (25)	0 (0)	8 (8.1)	0 (0)
Malignancy	6 (5.7)	2 (3.3)	1 (3.6)	3 (16.7)	5 (5.0)	1 (14.3)
Kidney Diseases	4 (3.8)	0 (0)	4 (14.3)	0 (0)	9 (9)	0 (0)
Respiratory Disorder	19 (17.9)	2 (3.3)	17 (60.7)	0 (0)	19 (19.0)	0 (0)
Combined severe diseases ^d	34 (32.1)	7 (11.7)	24 (85.7)	3 (16.7)	33 (33.3)	1 (14.3)
Laboratory results	n =99	n = 53	n = 28	n = 18	n =93	n =6
Haemoglobin (g/dL) ^a	12.9 (2.1)	13.1 (1.7)	11.7 (2.4)	13.8 (2.0)	37.5 (5.99)	37.6 (6.27)
Anaemia, n (%)	30 (30.3)	10 (18.9)	4 (22.2)	16 (57.1)	12.8 (2.07)	13.1 (2.23)
Haematocrit (%) ^a	37.5 (6.0)	38.7 (4.7)	34 (7.0)	39.4 (5.6)	37.5 (5.99)	37.6 (6.28)
Leucocyte $(10^3/\mu L)^a$	10.3 (7.1-16.4)	8 (5.71-11.8)	16.1 (11.2-21.5)	7.06 (3.88-10.3)	10.2 (6.53-14.3)	12.8 (8.48-15.3)
≤10, n (%)	46 (46.9)	33 (63.5)	4 (14.3)	9 (50.0)	44 (47.8)	2 (33.3)
>10, n (%)	52 (53.1)	19 (36.5)	24 (85.7)	9 (50.0)	48 (52.2)	4 (66.7)
Thrombocyte $(10^3/\mu L)^a$	268 (198-347)	236 (188-320)	320 (239-394)	293 (210-328)	268 (207-345)	202 (157-215)
<150, n (%)	6 (6.2)	4 (7.8)	1 (3.6)	1 (5.6)	5 (5.5)	1(16.7)
150-450, n (%)	84 (86.6)	45 (88.2)	22 (78.6)	17 (94.4)	79 (86.8)	5 (83.3)
>450, n (%)	7 (7.2)	2 (3.9)	5 (17.9)	0 (0)	7 (7.7)	0 (0)
	n =71	n = 52	n=28	n = 18	n = 86	n = 6
Lymphocyte (%)	11.9 (8.36-24.7)	22.6 (11.9-36.6)	9.45 (3.83-11.8)	21.8 (10.4-26.4)	14.1 (8.39-25.4)	7 (4.70-8.75)
<20	58 (63.0)	19 (41.3)	26 (82.9)	13 (72.2)	53 (60.9)	6 (100)
20-40	25 (27.2)	18 (39.1)	5 (27.8)	2 (7.1)	25 (28.7)	0 (0)
>40	9 (9.9)	9 (19.6)	0 (0)	0 (0)	9 (10.3)	0 (0)
Basophil (%)	0.4 (0.2-0.68)	0.6 (0.31-0.99)	0.2 (0.1- 0.4)	0.2 (0.1-1.8)	0.3 (0.2 - 0.6)	0.2 (0.1- 0.28)
Eosinophil (%)	0.4 (0.04-1.8)	0.46 (0.16-1.98)	0.15 (0-1.43)	0 (0 - 0.8)	0.3 (0.0-1.8)	0.1 (0.0 - 0.25)
Neutrophil (%)	76.7 (65.3-86.3)	67.7 (52.3-78.9)	82.7 (75.9-90.5)	80.3 (70.8-90.0)	76.7 (66.3-84.8)	88.7 (86.2-91.4)

Characteristics	All	Non (COVID-19	COVID-19	Survivor	Death
		Suspected	Lung infection	Confirmed		
	n= 106	n = 60	n=28	n = 18	n=99	n=7
Monocyte (%)	7.25 (5.4-9.95)	7.8 (6.15-10.0)	6.85 (4.95-11.0)	6.4 (2.8-9.6)	7.2 (5.4-9.5)	3.9 (2.8-5.0)
Chest radiograph abnormality, n (%)	n=106	N=60	N=28	N=18	N=97	N=7
Pneumonia	76 (71.7)	32 (53.3)	27 (96.4)	17 (94.4)	0 (0)	7 (100)
Cardiomegaly	10 (9.4)	2 (3.3)	7 (25.0)	1 (5.6)	9 (9.9)	0 (0)
Within normal	17 (16.0)	15 (25.0)	1 (3.6)	1 (5.6)	17 (17.2)	0 (0)
Consolidation	20 (18.9)	11 (18.3)	8 (28.6)	1 (5.6)	19 (19.2)	1 (14.3)
Patchy/Infiltration/ Interstitial	76 (71.7)	32 (53.2)	27 (96.4)	17 (94.4)	69 (69.7)	7 (100)
Abnormality, n (%)						
Glasgow Coma Scale <15	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Respiratory Distress	51 (48.1)	18 (30.0)	24 (85.7)	9 (50.0)	45 (45.5)	6 (85.7)
Systolic Pressure <100 mmHg	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Discharge diagnosis, n (%)						
COVID-19 infection	18 (17.2)	0 (0)	18 (100)	0 (0)	12 (12.1)	6 (85.7)
Community Acquired Pneumonia	47 (44.3)	19 (31.7)	0 (0)	28 (100)	47 (47.5)	0 (0)
Viral Infection	11 (18.3)	11 (18.3)	0 (0)	0 (0)	11 (11.1)	0 (0)
Acute Bronchitis	6 (5.6)	6 (10.0)	0 (0)	9 (0)	6 (6.1)	0 (0)
Upper Respiratory Infection	10 (9.4)	10 (16.7)	0 (0)	0 (0)	10 (10.1)	0 (0)
Other diseases	6 (5.4)	6 (10.2)	0 (0)	0 (0)	5 (5.0)	1(14.3)
Not yet discharged	8 (7.5)	8 (13.3)	0 (0)	0 (0)	8 (8.1)	0 (0)

GIT gastrointestinal; TB lung tuberculosis, including TB and other respiratory diseases.

a Presented as mean (SD); or as median (25th-75th percentile)

b Assessed at admission

^c Heart disease included coronary artery disease, atrial fibrillation, congestive heart failure, and atherosclerotic heart disease. ^d Severe diseases included Heart disease, Kidney diseases, Lung TB, other respiratory and severe Diseases

In univariate logistic regression, age \geq 45 years, positive history of contact, and pneumonia by chest x-ray, were significantly associated with higher risk of SARS-CoV-2 infection. Among all symptoms, runny nose tended toward lower risk for infection. Hypertension and malignancy were comorbidities significantly associated with confirmed cases (Table 2). Multivariate logistic regression found that age \geq 45 years (aOR 7.81; 95% CI 1.61- 38.0), travel history to an affected area (aOR 63.2; 95% CI 4.65-858.9), history of contact with a COVID-19 positive patient (aOR 232; 95% CI 15.1-3569) and pneumonia by chest x-ray (aOR 31.5; 95% CI 1.74-571.3) were independently associated with SARS-CoV-2 infection.

Among all patients, including 7 deaths and 99 survivors, univariate analysis (Table 3) showed that age ≥ 45 years, international travel, contact with confirmed COVID-19 case, and diabetes mellitus were associated with death. Dyspnoea tended toward increased risk for death. In the multivariate logistic regression, travel history, presence of history of contact with confirmed COVID-19 cases, and diabetes mellitus retained significant association with mortality. No significant associations were observed between laboratory markers and death. Gender was not associated with SARS-CoV-2 infection or death.

Table 2. Univariate and multivariate logistic regression analyses for predictors of SARS-CoV-2 infection (n=106)

Characteristic			Confirm	ned COVID-	19 positiv	ve	
	-		Univariate			Multivariate	
	n (%)	β	OR (95% CI)	P value	β	OR (95% CI)	P value
Demography							
Age category, year							
<45	4 (22.2)		1 (ref)				
>=45	14 (77.8)	1.44	4.2 (1.28 - 13.8)*	0.02	2.06	7. 81 (1.61 – 38.0)*	0.011
Gender							
Female	6 (33.3)		1 (ref)				
Male	12 (66.7)	0.74	2.09 (0.72 - 6.07)	0.17			
Travel History							
No	9 (50.0)		1 (ref)				
Yes	9 (50.0)	-0.32	0.73 (0.26 - 2.0)	0.54	4.15	63.2 (4.65 - 859)**	0.002
History of Contact							
No	9 (50.0)		1 (ref)				
Yes	9 (50.0)	2.05	7.8 (2.51 - 24.3)***	< 0.001	5.45	232 (15.1 - 3569)***	< 0.001
Symptoms							
Fever							
No	3 (16.7)		1 (ref)				
Yes	15 (83.3)	0.28	1.33 (0.41 - 5.47)	0.67			
Cough							
No	2 (11.1)		1 (ref)				
Yes	16 (88.9)	0.33	1.39 (0.38 - 7.53)	0.66			
Sore throat							
No	18 (100)		1 (ref)				
Yes	0 (0.0)	-1.7	0.18 (0.001 - 1.52)	0.27			
Runny Nose			,				
No	18 (100)		1 (ref)				
Yes	0 (0.0)	-2.41	0.09 (<0.001 - 0.72)	0.08			

Characteristic			Confir	ned COVID-	19 positiv	ve	
			Univariate		_	Multivariate	
	n (%)	β	OR (95% CI)	P value	β	OR (95% CI)	P value
Dyspnoea							
No	9 (50.0)		1 (ref)				
Yes	9 (50.0)	0.09	1.09 (0.4 - 2.98)	0.86			
GI Tract Complaints							
No	18 (100)		1 (ref)				
Yes	0 (0.0)	-0.89	0.41 (0.003 - 3.89)	0.59			
Headache							
No	18 (100)		1 (ref)				
Yes	0 (0.0)	-1.36	0.26 (0.002 - 2.22)	0.38			
Radiology abnormalities							
Pneumonia							
No	1 (5.6)		1 (ref)				
Yes	17 (94.4)	2.12	8.36 (1.06 - 65.9)*	0.04	3.45	31.5 (1.74 - 571)*	0.02
Cardiomegaly							
No	17 (94.4)		1 (ref)				
Yes	1 (5.6)	-0.66	0.52 (0.06 - 4.35)	0.54			
Coexisting diseases							
Any							
No	10 (55.6)		1 (ref)				
Yes	8 (44.4)	0.10	1.10 (0.40 - 3.06)	0.85			
Diabetes Mellitus							
No	13 (72.2)		1 (ref)				
Yes	5 (27.8)	1.14	3.38 (0.98 - 11.7)	0.06	1.5	4.47 (0.43 - 46.2)	0.21
Hypertension							
No	13 (72.2)		1 (ref)				
Yes	5 (27.8)	1.35	3.85 (1.09 - 13.6)*	0.04	1.14	3.12 (0.35 - 28.1)	0.31

Characteristic			Confir	med COVID-	19 posit	ive	
			Univariate			Multivariate	
	n (%)	β	OR (95% CI)	P value	β	OR (95% CI)	P value
Malignancy							
No	15 (83.3)		1 (ref)				
Yes	3 (16.7)	1.74	5.67 (1.04 - 30.8)*	0.04			
Other severe diseases ^a							
No	15 (83.3)		1 (ref)				
Yes	3 (16.7)	-1.0	0.37 (0.1 - 1.37)	0.14			
Laboratory Results							
Anaemia							
No	4 (22.2)						
Yes	14 (77.8)	-0.46	0.63 (0.19 - 2.1)	0.45			
Leukopenia							
No	9 (50.0)	0.15	1.16 (0.42 - 3.23)	0.77			
Yes	9 (50.0)						
NLR^b							
< 3.13	3 (16.7)						
>= 3.13	15 (83.3)	0.02	1.02(0.98-1.05)	0.42			

NLR neutrophil-to-lymphocyte ratio.

a Other severe diseases: Heart disease, Kidney diseases, Lung TB, other respiratory and severe diseases.
bbased on Liu, et al(7)

***p-values < 0.001; **p-values < 0.01; *p-values < 0.05.

Table 3. Univariate and multivariate regression analyses for predictors of COVID-19 death (n=106)

Characteristic				Death			
			Univariate			Multivariate	
	n (%)	β	OR (95% CI)	P value	β	OR (95% CI)	P value
Demography							
Age category, year							
<45	0 (0)		1 (ref)				
>=45	7 (100)	2.81	16.6 (1.93 ->999)**	0.01	2.62	13.7 (0.87 - >999)	0.09
Gender							
Female	3 (42.9)		1 (ref)				
Male	4 (57.1)	0.23	1.26 (0.27 - 5.9)	0.77			
Travel History							
No	6 (85.7)		1 (ref)				
Yes	1 (14.3)	-2.18	0.11 (0.01 - 0.98)*	0.047	1.44	4.23 (0.25 – 92.9)*	0.04
History of Contact							
No	2 (28.6)		1 (ref)				
Yes	5 (71.4)	2.72	15.2 (2.68 – 86.0)	0.002	4.36	78.4 (4.85->999)**	0.01
Symptoms							
Fever							
No	2 (21.2)		1 (ref)				
Yes	5 (71.4)	-0.51	0.60(0.13 - 3.54)	0.53			
Cough							
No	1 (14.3)		1 (ref)				
Yes	6 (85.7)	0.15	1.16 (0.13 -10.3)	0.90			
Headache							
No	7 (100)		1 (ref)				
Yes	0 (0)	-0.33	0.72(0.005 - 6.86)	0.84			
Sore throat							
No	7 (100)		1 (ref)				
Yes	0 (0)	-0.67	0.51 (0.004 - 4.73)	0.67			

Characteristic				Death			
			Univariate			Multivariate	
	n (%)	β	OR (95% CI)	P value	β	OR (95% CI)	P value
Runny Nose							
No	7 (100)		1 (ref)				
Yes	0 (0)	-1.37	0.25 (0.002-2.25)	0.37			
Dyspnoea							
No	1 (14.3)		1 (ref)				
Yes	6 (85.7)	1.65	5.19 (1.04 – 51.1)	0.08			
GI Tract Complains							
No	7 (100)		1 (ref)				
Yes	0 (0)	0.14	$1.15 \ (0.008 - 11.9)$	0.94			
Radiology abnormalities							
Pneumonia							
No	0 (0)		1 (ref)				
Yes	7 (100)	18.9	6.58 (0.76-864)	0.21			
Cardiomegaly							
No	7 (100)		1 (ref)				
Yes	0 (0)	-0.66	0.52 (0.06 - 4.35)	0.54			
Coexisting diseases							
Any							
No	3 (42.9)		1 (ref)				
Yes	4 (57.1)	0.64	1.89 (0.4 - 8.88)	0.42			
Diabetes Mellitus							
No	3 (42.9)		1 (ref)				
Yes	4 (57.1)	2.47	11.9 (2.32 - 60.8)**	0.003	3.57	35.6 (2.92->999)*	0.02
Hypertension							
No	2 (28.6)		1 (ref)				
Yes	5 (71.4)	1.16	3.2 (0.55 - 18.5)	0.19			

Characteristic				Death			
			Univariate			Multivariate	
	n (%)	β	OR (95% CI)	P value	β	OR (95% CI)	P value
Malignancy							
No	1 (14.3)		1 (ref)				
Yes	6 (85.7)	1.14	3.13 (0.31 - 31.3)	0.33			
Heart Disease							
No	7 (100)		1 (ref)				
Yes	0 (0)	-0.34	0.71 (0.01-6.79)	0.82			
Kidney and Other Diseases							
No	7 (100)		1 (ref)				
Yes	0 (0)	-0.46	0.63 (0.01-5.91)	0.77			
Respiratory Illness ^a							
No	7 (100)		1 (ref)				
Yes	0 (0)	0.76	0.47 (0.004-4.26)	0.62			
Other severe diseases ^b							
No	1 (14.3)		1 (ref)				
Yes	6 (85.7)	-1.1	0.33 (0.04 - 2.88)	0.32			
Laboratory Results							
Anaemia							
No	3 (50.0)		1 (ref)				
Yes	3 (50.0)	0.93	2.54 (0.48 - 13.4)	0.27			
Leucocyte							
>10 K	4 (66.7)		1 (ref)				
<= 10 K	2 (33.3)	-0.61	0.55 (0.10 - 3.13)	0.50			
NLR ^c							
< 3.13	0 (0)						
>= 3.13	6 (100)	0.03	1.03(0.98-1.07)	0.21			

NLR neutrophil-to-lymphocyte ratio.

all neutrophil-to-lymphocyte ratio.

blue respiratory illness.

blue respiratory diseases, and severe diseases. blue respiratory diseases.

class of the respiratory diseases.

class of the respiratory diseases.

blue respiratory diseases.

class of the respiratory

Results for the HCA of symptoms are seen in the dendrogram (Figure 1). HCA cluster 1 (HCA-C1) comprised 7 (38.9%) confirmed, 17 (28.3%) suspected, and 1 (3.6%) lung infection cases. Patients reported predominantly fever with cough, with some also reporting sore throat and GIC, but none with dyspnoea. HCA-C2 comprised 2 (11.1%) confirmed, 11 (18.3%) suspected, and 5 (17.9%) lung infection cases. Patients had predominantly fever, with few combined with dyspnoea, and runny nose. However, cough was not a primary symptom, and none had GIC. Most importantly, patients had fewer symptoms compared to other HCA clusters, and with some reporting no symptoms. HCA-C3 comprised of 17 (28.3%) suspected, but no confirmed or lung infection cases. Patients tended to present with more symptoms, typically 3-5, which were mainly fever, cough, headache, runny nose, and sore throat. A few experienced dyspnoeas and none had GIC. HCA-C4 comprised 1 (5.6%) confirmed, 4 (6.7%) suspected, and 6 (21.4%) lung infection cases. All reported only cough and dyspnoea. HCA-C5 comprised 8 (44.4%) confirmed, 11 (18.3%) suspected and 16 (57%) lung infection cases. All exhibited cough, dyspnoea, and fever.

The PCA for symptoms revealed two components. PCA symptom 1 (PCA-S1) represented the covariance pattern of patients with headache, runny nose, sore throat, and less dyspnoea with factor loadings of 0.47, 0.43, 0.45, and -0.5, respectively, and accounted for 30% of the total variance across symptoms. PCA-S2 represented a pattern of fever, cough, and GIC with factor loadings of 0.65, 0.51 and 0.63, respectively, and accounted for 18% of variance. The PCA for haematology revealed three components. PCA-H1 represented haemoglobin and haematocrit with loadings of 0.54 and 0.52 and accounted for 42% of total variance. PCA-H2 represented lymphocyte and neutrophil counts with loadings of 0.76 and -0.83 and accounted for 18% of variance. PCA-H3 had a high factor loading of 1.15 for monocytes and tended toward lower factor loadings of -0.05, -0.05, -0.02, 0.09, -0.12, -0.05, 0.13 and -0.05 for haemoglobin, haematocrit, thrombocytes, leucocytes, lymphocytes, basophils, neutrophils, and eosinophils, respectively, and accounted for 14% of total

variance.

Univariate logistic regression of symptom data on SARS-CoV-2 infection revealed that runny nose tended toward decreased risk (OR 0.1; 95%CI < 0.001 – 0.83; p = 0.08). No other symptoms exhibited associations in either univariate or multivariate analysis (Table 4). Multivariate analysis of HCA groups revealed that HCA-C3 tended toward reduced risk of COVID-19 cases (aOR 0.048; 95%CI < 0.01 – 0.52; p = 0.056). HCA-C3 comprised patients with symptoms of fever, cough, headache, runny nose, or sore throat, in which only a few experienced dyspnoea, and none had GIC. No other clusters showed any significant associations with COVID-19 cases. However, in all multivariate models with HCA predictors, age \geq 45 years, presence of international travel history, previous contact with a COVID-19 patient, and pneumonia by x-ray were significant associations, consistent with previous results. For mortality, none of the symptoms nor HCA clusters showed any association in univariate or multivariate analyses (Table 5). However, the presence of diabetes and history of contact with COVID-19 patients were consistently associated with higher mortality in all HCA models.

Table 4. Univariate and multivariate logistic regression analyses of HCA clusters and SARS-CoV-2 infection (n=106)

Tright Fig. Tright Fig. Tright Fig. Fig. Tright Fig.	C-4	Un	ivariate COVID-1	9 case		Multivariate HCA	1		Multivariate HCA	. 2		Multivariate HCA	13		Multivariate HC	A 4		Multivariate HC	A 5
Tarvel 2.18 3.18 0.11 0.047 3.08 2.17 0.005 3.1 2.75 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5	Category	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P
Trace 2-18 0.11 0.047 3.08 21.7 0.005 3.21 24.7 0.002 3.56 35.3 0.001 3.25 25.7 0.002 3.67 3.93	Age	1.44	4.2	0.02	1.94	6.96	0.01	1.78	5.94	0.02	2	7.35	0.01	1.82	6.18	0.02	1.67	5.32	0.03
History Contact 2.05 7.8 0.01 9.08	-		$(1.28 - 13.8)^*$			$(1.69 - 35.8)^*$			$(1.46 - 30.2)^*$			$(1.68 - 39.2)^*$			(1.56 - 29.8)			$(1.32 - 25.5)^*$	
Contact Cont	Travel	-2.18		0.047	3.08		0.005	3.21		0.002	3.56		0.001	3.25	25.7	0.002	3.67		0.001
History (2.51 - 24.3)* (10.9 - 2999)*** (11.3 - 2999)*** (11.8 - 2999)*** (11.8 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)*** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 - 2999)** (11.9 -	History		$(0.01 - 0.98)^*$															$(5.27 - 557)^{**}$	
Name of the process o		2.05		< 0.001	4.40	81.5	< 0.001	4.34	76.6	< 0.001	4.94		< 0.001	4.36		< 0.001	4.76	117	< 0.001
Prelimonia 1.06 - 65.95 1.14 3.38 0.06 1.51 4.53 0.18 1.22 3.4 0.24 1.32 3.76 0.24 1.25 3.49 0.23 1.23 3.43 0.06 0.98 1.17 0.053 - 59.51 0.047 - 32.65 0.043 - 56.2 0.049 - 23.11 0.046 - 31.8) Hyper	History														$(10.9 - >999)^{***}$			(14.5 - >999)***	
Diabetes 1.14 3.38 0.06 1.51 4.53 0.18 1.22 3.4 0.24 1.32 3.76 0.24 1.25 3.49 0.23 1.23 3.43	Xray	2.12		0.04	2.28		0.03	2.6		0.03	2.99		0.03	2.59		0.02	2.52		0.03
Hyper 1.35 3.85 0.04 0.68 1.98 0.54 1.01 2.75 0.31 1.01 2.73 0.34 1.06 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 3.44 1.05 0.68 0.29 1.23 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15																			
Hyper- 1.35	Diabetes	1.14		0.06	1.51		0.18	1.22		0.24	1.32		0.24	1.25		0.23	1.23		0.24
tension (1.09 - 13.6)* (0.20 - 20.4) (0.38 - 21.4) (0.33 - 25.9) (0.04 - 5.55) (0.49 - 27.0) Fever 0.46 1.58 0.49 (0.47 - 6.73) Cough 0.29 1.34 0.71 (0.31 - 8.02) Headache -0.46 0.63 0.78 (0.004 - 11.5) Runny nose -2.3 0.1 0.08 (-0.001 - 0.83) Sore throat -0.96 0.39 0.50 (0.003 - 4.1) Dyspnoca -0.7 0.5 0.20 (0.16 - 1.47) GIT -0.77 0.46 0.63 (0.003 - 5.89) HCA-C1* 0.77 2.15 0.17 1.07 2.91 0.18 (0.64 - 14.8)																			
Fever 0.46 1.58 0.49 (0.47 - 6.73) Cough 0.29 1.34 0.71 (0.31 - 8.02) Headache -0.46 0.63 0.78 (0.004 - 11.5) Runny nose -2.3 0.1 0.08 (<0.001 - 0.83) Sore throat -0.96 0.39 0.50 (0.003 - 4.1) Dyspnoea -0.7 0.5 0.20 (0.16 - 1.47) GIT -0.77 0.46 0.63 (0.003 - 5.89) HCA-C1 ^a 0.77 2.15 0.17 1.07 2.91 0.18 (0.64 - 14.8)	* *	1.35		0.04	0.68		0.54	1.01		0.31	1.01		0.34	1.06		0.29	1.23		0.22
Cough 0.29 1.34 0.71 Headache -0.46 0.63 0.78 (0.004 - 11.5) Runny nose -2.3 0.1 0.08 Sore throat -0.96 0.39 0.50 (0.003 - 4.1) Dyspnoea -0.7 0.5 0.20 GIT -0.77 0.46 0.63 Problem (0.003 - 5.89) HCA-C1a 0.77 2.15 0.17 1.07 2.91 0.18 (0.69 - 6.31) (0.64 - 14.8)						(0.20 - 20.4)			(0.38 - 21.4)			(0.33 - 25.9)			(0.04 - 5.55)			(0.49 - 27.0)	
Cough 0.29 1.34 0.71 (0.31 - 8.02) Headache -0.46 0.63 0.78 (0.004 - 11.5) Runny nose -2.3 0.1 0.08 (<0.001 - 0.83) Sore throat -0.96 0.39 0.50 (0.003 - 4.1) Dyspnoea -0.7 0.5 0.20 (0.16 - 1.47) GIT -0.77 0.46 0.63 Problem (0.003 - 5.89) HCA-C1a 0.77 2.15 0.17 1.07 2.91 0.18 (0.64 - 14.8)	Fever	0.46		0.49															
Headache																			
Headache -0.46	Cough	0.29		0.71															
Runny nose																			
Runny nose -2.3	Headache	-0.46		0.78															
Sore throat -0.96 0.39 0.50 (0.003 - 4.1)	D	2.2		0.00															
Sore throat -0.96	Runny nose	-2.3		0.08															
Dyspnoea -0.7	G 41 .	0.06	,	0.50															
Dyspnoea -0.7	Sore throat	-0.96		0.50															
GIT -0.77	Ъ	0.7		0.20															
GIT -0.77 0.46 0.63 Problem (0.003 - 5.89) HCA-Cl ^a 0.77 2.15 0.17 1.07 2.91 0.18 (0.69-6.31) (0.64 - 14.8)	Dyspnoea	-0./		0.20															
Problem (0.003 - 5.89) HCA-C1 ^a 0.77 2.15 0.17 1.07 2.91 0.18 (0.69-6.31) (0.64 - 14.8)	CIT	0.77		0.62															
HCA-C1 ^a 0.77 2.15 0.17 1.07 2.91 0.18 (0.69-6.31) (0.64 - 14.8)		-0.77		0.03															
(0.69-6.31) $(0.64-14.8)$	Problem		(0.003 - 3.89)																
(0.69-6.31) $(0.64-14.8)$	HCA-C1 ^a	0.77	2.15	0.17	1.07	2.91	0.18												
	HCA-C2b	-0.34	0.71	0.65		(*** * * ***)		0.17	1.19	0.87									
(0.13 - 2.61) $(0.12 - 8.86)$																			
$HCA-C3^{\circ}$ -2.15 0.12 0.15 -3.04 0.048 0.06	HCA-C3c	-2.15		0.15					(-3.04	0.048	0.06						
(<0.001 - 0.94)																			
$HCA-C4^{d}$ -0.39 0.68 0.69 -0.38 0.68 0.75	HCA-C4 ^d	-0.39	(0.69								/		-0.38	0.68	0.75			
(0.07 - 3.23)															(0.04 - 5.55)				
HCA-C5° 0.69 2.0 0.19	HCA-C5 ^e	0.69		0.19											, ,		0.99	2.71	0.18
(0.7-5.64)			(0.7 - 5.64)															(0.62 - 12.6)	

HCA Hierarchical cluster analyses.

^aHCA-C1 (HCA cluster 1): Patients had predominantly fever with cough, with some also reporting sore throat and GI tract complaints, but none with dyspnoea.

^bHCA-C2 (HCA cluster 2): Patients had predominantly fever, with few combined with dyspnoea, and runny nose. However, coughing were not primary symptoms, and none had GIT problem.

^cHCA-C3 (HCA cluster 3): Patients tended to present with more symptoms, typically 3-5, which were mainly fever, cough, headache, runny nose, and sore throat. A few experienced dyspnoea and none had GI tract complaints.

^dHCA-C4 (HCA cluster 4): All reported only cough and dyspnoea.

°HCA-C5 (HCA cluster 5): All exhibited cough, dyspnoea, and fever.

***p-values < 0.001; **p-values < 0.01; *p-values < 0.05.

Table 5. Univariate and multivariate logistic regression analyses of HCA clusters and COVID-19 death (n=106)

Category	Uni	variate COVID-19) Death		Multivariate (HCA	1)		Multivariate HC	A 2		Multivariate HCA	A 3		Multivariate HCA	4	I	Multivariate HCA	5
	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P	β	OR (95% CI)	P
Age	2.81	16.6 (1.93 - >999)	0.01	2.74	15.4 (0.67 - >999)	0.12	1.98	7.23 (0.54 - >999)	0.17	2.0	7.41 (0.49 - >999)	0.17	1.69	5.44 (0.41 - 767)	0.22	1.96	7.11 (0.51 - >999)	0.18
Travel History	-2.18	0.11 $(0.01 - 0.98)^*$	0.047	2.44	11.5 (0.50 - >999)	0.12	1.41	4.09 (0.27 - 78.1)	0.28	1.43	4.18 (0.28 - 75.3)	0.27	1.03	2.8 (0.16 - 47.2)	0.42	2.23	9.27 (0.42 - >999)	0.13
Contact History	2.72	15.2 (2.68 – 86.0)	0.002	4.97	144 (6.45 - >999)*	0.004	4.01	55.0 (4.32 - >999)*	0.005	4.26	70.5 (5.14 - >999)**	0.004	3.93	51 (4.28 - >999)**	0.004	4.78	118.7 (5.16 - >999)**	0.01
X-ray Pneumonia	18.9	6.58 (0.76 - 864)	0.21	1.79	6.01 (0.35 - >999)	0.26	1.69	5.44 (0.33 - >999)*	0.29	1.28	3.6 (0.22 - 651)	0.39	1.32	3.73 (0.26 - 546)	0.37	1.14	3.12 (0.20 - 545)	0.44
Diabetes	2.47	11.9 (2.32 - 60.8)**	0.003	3.09	22.0 (1.44 - >999)*	0.039	3.19	24.4 (2.1 - >999)	0.02	3.15	23.4 (1.83 - >999)*	0.03	2.95	19 (1.75 - >999)*	0.03	3.45	31.4 (1.84 - >999)*	0.02
Hypertension	1.16	3.2 (0.55 - 18.5)	0.19	1.13	3.09 (0.12 - 490)	0.45	-0.16	0.85 (0.055 - 8.31)	0.89	-0.41	0.67 (0.04 - 6.37)	0.74	-0.19	0.83 (0.07 - 7.76)	0.87	-0.05	3.88 $(0.45 - 66.5)$	0.97
Fever	-0.37	0.69 (0.15 - 4.14)	0.64		(***-			(******			(****			(****, *****)			(41.12 44.15)	
Cough	-0.71	0.49 (0.061 - 5.16)	0.45															
Headache	0.84	2.32 (0.012 - 125)	0.61															
Runny nose	-0.41	0.67 (0.005 - 7.46)	0.75															
Sore throat	-0.34	0.71 (0.002 - 13.1)	0.82															
Dyspnoea	1.18	3.26 (0.61 - 35.5)	0.18															
GIT Problem	0.69	2.0 (0.007 - 47.6)	0.68															
HCA-C1 ^a	-1.6	0.2 (0.002 - 1.77)	0.29	2.84	0.06 (<0.001 - 2.02)	0.17												
HCA-C2 ^b	0.072	1.07 (0.11 - 5.6)	0.94		(30.001 2.02)		0.87	2.4 (0.16 - 45.5)	0.48									
HCA-C3 ^c	-1.17	0.31 (0.002 - 2.76)	0.44					(0.10 - 43.3)		-1.35	0.26 (0.002 - 3.83)	0.4						
HCA-C4 ^d	0.67	1.95 (0.19 -10.7)	0.51								(0.002 - 3.83)		1.07	2.93 (0.13 - 51.5)	0.44			
HCA-C5 ^e	1.6	(0.19 - 10.7) 4.94 (1.12 - 28.8)*	0.046											(0.13 - 31.3)		1.36	3.88 (0.45 - 66.5)	0.20

HCA Hierarchical cluster analyses.

^aHCA-C1 (HCA cluster 1): Patients had predominantly fever with cough, with some also reporting sore throat and GI tract complaints, but none with dyspnoea.

^bHCA-C2 (HCA cluster 2): Patients had predominantly fever, with few combined with dyspnoea, and runny nose. However, coughing were not primary symptoms, and none had GIT problem.

^cHCA-C3 (HCA cluster 3): Patients tended to present with more symptoms, typically 3-5, which were mainly fever, cough, headache, runny nose, and sore throat. A few experienced dyspnoea and none had GI tract complaints.

^dHCA-C4 (HCA cluster 4): All reported only cough and dyspnoea.

°HCA-C5 (HCA cluster 5): All exhibited cough, dyspnoea, and fever.

**p-values < 0.01; *p-values < 0.05.

Analysis of PCA revealed a symptom component for fever, cough, and GIC that tended to increase risk of infection (OR 3.41; 95% CI 1.06-14; p=0.06), and a haematology component with elevated monocytes decreased risk (OR 0.26; 95%CI 0.07-0.79; p=0.027) (Table 6). Multivariate models that included either PCA clusters or the individual predictors were consistent in that presence of travel history and contact with COVID-19 patients were significant predictors of COVID-19 cases.

In univariate analyses for death, HCA-C5 of cough, fever and dyspnoea had increased risk (OR 5.75; P5%CI 1.06 - 31.3, p=0.043). No other individual symptoms or haematology measures, nor HCA clusters or PCA components were associated with death in univariate or multivariate analyses (Table 7). However, we note that diabetes tended toward increased risk for death (aOR 8.86; 95%CI 0.72 – 17.0; p = 0.07), and that history of contact with COVID-19 cases was consistently associated with death (aOR 28.6; 95%CI 1.63->999.9; p = 0.01).

Table 6. Univariate and multivariate logistic regression analyses of PCA components and SARS-CoV-2 infection (n=106)

Category		Univariate COVID-19 c	ase		Multivariate PCA Symptom & Haematolog	y		Multivariate PCA Symptom			Multivariate PCA Haematology	
<i>.</i>	β	OR (95% CI)	P	β	aOR (95% CI)	P	β	aOR (95% CI)	P	β	aOR (95% CI)	P
Age	1.44	4.20 (1.28 - 13.8)*	0.02	2.03	7.58 (1.36 - 61.6)	0.03	2.20	9.01 (1.73 - 65.8)	0.01	1.66	5.26 (1.24 - 27.8)*	0.03
Travel History	-2.18	0.11 (0.01 - 0.98)*	0.047	2.73	15.4 (1.65 - >999)	0.02	2.97	19.5 (3.21 – 216)	0.003	3.07	21.5 (2.60 - 387)**	0.01
Contact History	2.05	7.80 (2.51 - 24.3)***	< 0.001	4.00	54.8 (5.08 - >999)	0.002	4.21	67.5 (9.13 - >999)	< 0.001	4.07	58.6 (7.49 - >999)***	< 0.001
Xray Pneumonia	2.12	8.36 (1.06 - 65.9)*	0.04	1.28	3.60 (0.38 - 84.8)	0.24	2.06	7.87 (0.89 - 168)	0.08	1.70	5.46 (0.99 - 59.1)	0.07
Diabetes	1.14	3.38 (0.98- 11.7)	0.06	0.77	2.13 (0.16 - 72.7)	0.51	1.04	2.82 (0.28 - 39.4)	0.36	1.16	3.19 (0.24 - 69.6)	0.34
Hypertension	1.35	3.85 (1.09 - 13.6)*	0.04	0.69	1.99 (0.05 - 82.9)	0.62	0.22	1.25 (0.09 - 14.8)	0.85	0.99	2.68 (0.19 – 47.0)	0.41
Fever	0.46	1.58 (0.47 - 6.73)	0.49									
Cough	0.29	1.34 (0.31 - 8.02)	0.71									
Headache	-0.46	0.63 (0.004 - 11.5)	0.78									
Runny nose	-2.30	0.10 (<0.001 - 0.83)	0.08									
Sore throat	-0.96	0.39 (0.003 - 4.10)	0.50									
Dyspnoea	-0.70	0.50 (0.16 - 1.47)	0.20									
GIT Problem	-0.77	0.46 (0.003 - 5.89)	0.63									
PCA-S1 (1) ^a	0.58	1.79 (0.57 - 5.59)	0.32	0.28	1.32 (0.11 - 12.8)	0.79	0.84	2.31 (0.36 - 19.3)	0.37			
PCA-S1 (2) ^b	-1.10	0.33 (0.06 -1.30)	0.15	0.51	1.67 (0.05 - 63.6)	0.72	0.21	1.23 (0.06 - 23.4)	0.88			
PCA-S2 (1) ^c	1.23	3.41 (1.06 – 14.0)	0.06	1.13	3.10 (0.24 - 177)	0.31	0.69	1.99 (0.27 - 25.7)	0.49			
PCA-S2 (2) ^d	-1.33	0.27 (0.002 - 2.97)	0.40	-2.74	0.06 (<0.001 - 1.70)	0.13	-2.62	0.07 (<0.001 - 1.48)	0.14			
PCA-H1 (1) ^e	0.06	1.07 (0.25 - 4.48)	0.93	-0.09	0.91 (0.10 - 9.64)	0.92				0.13	1.14 (0.18 – 8.10)	0.88
PCA-H1 (2) ^f	1.05	2.86 (0.89 - 10.6)	0.10	0.94	2.56 (0.34 - 29.8)	0.32				0.75	2.13 (0.43 – 12.3)	0.35
PCA-H2 (1) ^g	-0.96	0.39 (0.09 - 1.39)	0.17	-1.24	0.29 (0.02 - 2.81)	0.24				-1.39	0.25 (0.03 – 1.69)	0.15
PCA-H2 (2) ^h	-0.19	0.82 (0.27 - 2.51)	0.74	0.42	1.53 (0.20 - 3.04)	0.66				-0.54	0.58 (0.09 – 3.44)	0.53
PCA-H3 (1) ⁱ	-1.36	0.26 (0.07 - 0.79)*	0.03	-0.34	0.71 (0.11 - 4.75)	0.69				-0.79	0.45 (0.08 – 2.19)	0.33
PCA-H3 (2) ^j	-1.83	0.16 (0.03 - 0.61)*	0.02	-1.29	0.28 (0.01 - 3.47)	0.26				-1.13	0.32(0.03 - 2.05)	0.23

PCA Principal component analyses.

^aPCA-S1 (1) (PCA Symptom 1, 2nd tertile vs 1st tertile): Headache, runny nose, sore throat, and less dyspnoea with factor loadings of 0.47, 0.43, 0.45, and -0.5, respectively.

^bPCA-S1 (2) (PCA Symptom 1, 3rd tertile vs 1st tertile): Headache, runny nose, sore throat, and less dyspnoea with factor loadings of 0.47, 0.43, 0.45, and -0.5, respectively.

[°]PCA-S2 (1) (PCA Symptom 2, 2nd tertile vs 1st tertile): Fever, cough, and GI tract complaints with factor loadings of 0.65, 0.51 and 0.63, respectively.

^dPCA-S2 (2) (PCA Symptom 2, 3rd tertile vs 1st tertile): Fever, cough, and GI tract complaints with factor loadings of 0.65, 0.51 and 0.63, respectively.

ePCA-H1 (1) (PCA Haematology 1, 2nd tertile vs 1st tertile): Haemoglobin and haematocrit with factor loadings of 0.54 and 0.52, respectively.

^fPCA-H1 (2) (PCA Haematology 1, 3rd tertile vs 1st tertile): Haemoglobin and haematocrit with factor loadings of 0.54 and 0.52, respectively.

gPCA-H2 (1) (PCA Haematology 2, 2nd tertile vs 1st tertile): Lymphocyte and neutrophil counts with factor loadings of 0.76 and -0.83, respectively.

^hPCA-H2 (2) (PCA Haematology 2, 3rd tertile vs 1st tertile): Lymphocyte and neutrophil counts with factor loadings of 0.76 and -0.83, respectively.

ⁱPCA-H3 (1) (PCA Haematology 3, 2nd tertile vs 1st tertile): Haemoglobin, haematocrit, thrombocyte, leucocyte, monocyte, lymphocyte, basophil, neutrophil, and eosinophil with factor loadings of -0.05, -0.05, -0.05, -0.02, 0.09, 1.15, -0.12, -0.05, 0.13 and -0.05 respectively.

^jPCA-H3 (2) (PCA Haematology 3, 3rd tertile vs 1st tertile): Haemoglobin, haematocrit, thrombocyte, leucocyte, monocyte, lymphocyte, basophil, neutrophil, and eosinophil with factor loadings of -0.05, -0.05, -0.05, -0.02, 0.09, 1.15, -0.12, -0.05, 0.13 and -0.05 respectively.

***p-values < 0.001; **p-values < 0.01; *p-values < 0.05.

Table 7. Univariate and multivariate logistic regression analyses of PCA components and COVID-19 death (n=106)

Category	Univariate COVID-19 death			Multivariate PCA Symptom & Haematology			Multivariate PCA Symptom			Multivariate PCA Haematology		
	β	OR (95% CI)	P	β	OR*(95% CI)	P	β	OR*(95% CI)	P	β	OR*(95% CI)	P
Age	2.81	16.6 (1.93 - >999)**	0.01	1.77	5.86 (0.40 - > 999)	0.14	1.84	6.28 (0.21 - >999)	0.23	2.85	17.4 (0.68 - >999)	0.08
Travel History	-2.18	$0.11 (0.01 - 0.98)^*$	0.047	1.15	3.15 (0.04 - 613)	0.38	1.81	6.08 (0.31 - >999)	0.17	1.60	4.97 (0.12 - >999)	0.28
Contact History	2.72	15.2 (2.68 – 86.0)**	0.002	3.35	28.6 (1.63 -> 999)**	0.01	4.43	84.2 (5.66 - >999)**	0.002	3.81	44.9 (2.35 - 87.6)**	0.01
Xray Pneumonia	18.9	6.58 (0.76 - 864)	0.21	1.05	2.86 (0.08 - 377)	0.41	2.09	8.08 (0.27 - >999)	0.21	0.96	2.62 (0.002 - >999)	0.51
Diabetes	2.47	11.9 (2.32 - 60.8)**	0.003	2.18	8.86 (0.72 - 17.0)	0.07	2.30	10.0 (0.82 - >999)	0.07	3.04	20.8 (1.27 - >999)*	0.03
Hypertension	1.16	3.2 (0.55 - 18.5)	0.19	0.36	1.43 (0.08 - 64.8)	0.76	0.67	1.95 (0.12 - 192)	0.60	0.35	1.42 (0.047 - 582)	0.79
Fever	-0.37	0.69 (0.15 - 4.14)	0.64									
Cough	-0.71	0.49 (0.06 - 5.16)	0.45									
Headache	0.84	2.32 (0.01 - 125)	0.61									
Runny nose	-0.41	0.67 (0.005 - 7.46)	0.75									
Sore throat	-0.34	0.71 (0.002 - 13.1)	0.82									
Dyspnoea	1.18	3.26 (0.61 - 35.5)	0.18									
GIT Problem	0.69	2.0 (0.007 - 47.6)	0.68									
PCA-S1 (1) ^a	-2.13	0.12 (<0.001 - 1.08)	0.16	-1.70	0.18 (< 0.001 - 0.36)	0.25	-2.37	0.09 (<0.001 - 1.76)	0.14			
PCA-S1 (2) ^b	-1.33	0.26 (0.03 - 1.35)	0.16	-0.07	0.51 (< 0.001 - 65.8)	0.66	-0.70	0.49 (0.01 - 108)	0.67			
PCA-S2 (1) ^c	0.42	1.52 (0.34 - 8.86)	0.60	-0.35	0.71 (0.03 - 21.8)	0.76	-0.48	0.62 (0.04 - 38.4)	0.70			
PCA-S2 (2) ^d	-0.96	0.38 (0.003 - 5.05)	0.55	0.85	2.33 (< 0.001 - 204)	0.56	-1.02	0.36 (<0.001 - 15.8)	0.59			
PCA-H1 (1) ^e	-0.31	0.74 (0.12 - 4.04)	0.73	1.03	2.79 (0.15 - 5.43)	0.33				1.11	3.04 (0.16 - >999)	0.36
PCA-H1 (2) ^f	-0.37	0.69 (0.11 - 3.79)	0.68	-0.43	0.65 (0.002 - 19.8)	0.73				-1.58	0.21 (<0.001- 5.18)	0.29
PCA-H2 (1) ^g	-0.79	0.46 (0.08 - 2.05)	0.33	-0.07	0.93 (0.06 - 18.3)	0.94				-0.07	0.93 (0.04 - 36.9)	0.96
PCA-H2 (2) ^h	-2.57	0.08 (<0.001 - 0.72)	0.09	-1.30	0.27 (<0.001 - 0.54)	0.26				-1.81	0.16 (<0.001 - 2.42)	0.18
PCA-H3 (1) ⁱ	-0.94	0.39 (0.07 - 1.76)	0.25	-1.53	0.22 (<0.001 - 3.09)	0.22				-1.78	0.17 (<0.001 - 3.84)	0.20
PCA-H3 (2) ^j	-2.43	0.09 (<0.001 - 0.83)	0.11	-1.07	0.34 (0.005 - 5.33)	0.35				-1.82	0.16 (<0.001 - 2.15)	0.17

PCA Principal component analyses.

^aPCA-S1 (1) (PCA Symptom 1, 2nd tertile vs 1st tertile): Headache, runny nose, sore throat, and less dyspnoea with factor loadings of 0.47, 0.43, 0.45, and -0.5, respectively.

^bPCA-S1 (2) (PCA Symptom 1, 3rd tertile vs 1st tertile): Headache, runny nose, sore throat, and less dyspnoea with factor loadings of 0.47, 0.43, 0.45, and -0.5, respectively.

^cPCA-S2 (1) (PCA Symptom 2, 2nd tertile vs 1st tertile): Fever, cough, and GI tract complaints with factor loadings of 0.65, 0.51 and 0.63, respectively.

^dPCA-S2 (2) (PCA Symptom 2, 3rd tertile vs 1st tertile): Fever, cough, and GI tract complaints with factor loadings of 0.65, 0.51 and 0.63, respectively.

ePCA-H1 (1) (PCA Haematology 1, 2nd tertile vs 1st tertile): Haemoglobin and haematocrit with factor loadings of 0.54 and 0.52, respectively.

^fPCA-H1 (2) (PCA Haematology 1, 3rd tertile vs 1st tertile): Haemoglobin and haematocrit with factor loadings of 0.54 and 0.52, respectively.

gPCA-H2 (1) (PCA Haematology 2, 2nd tertile vs 1st tertile): Lymphocyte and neutrophil counts with factor loadings of 0.76 and -0.83, respectively.

^hPCA-H2 (2) (PCA Haematology 2, 3rd tertile vs 1st tertile): Lymphocyte and neutrophil counts with factor loadings of 0.76 and -0.83, respectively.

ⁱPCA-H3 (1) (PCA Haematology 3, 2nd tertile vs 1st tertile): Haemoglobin, haematocrit, thrombocyte, leucocyte, monocyte, lymphocyte, basophil, neutrophil, and eosinophil with factor loadings of -0.05, -0.05, -0.05, -0.02, 0.09, 1.15, -0.12, -0.05, 0.13 and -0.05 respectively.

^jPCA-H3 (2) (PCA Haematology 3, 3rd tertile vs 1st tertile): Haemoglobin, haematocrit, thrombocyte, leucocyte, monocyte, lymphocyte, basophil, neutrophil, and eosinophil with factor loadings of -0.05, -0.05, -0.02, 0.09, 1.15, -0.12, -0.05, 0.13 and -0.05 respectively.

**p-values < 0.01; *p-values < 0.05.

Discussion

To our knowledge, this is the first report of confirmed and suspected cases of COVID-19 in Indonesia. It is unique in examining patterns, clusters, or covariance constructs of symptoms and haematological data, or combinations thereof, with other predictors and their associations with key outcomes of infection and death.

The present study found consistent results in multivariate analyses for age \geq 45 years, presence of travel history, contact with a COVID-19 patient, and pneumonia by x-ray as significant predictors of COVID-19 cases. The associations persisted when adjusted with data for symptoms and haematology either individually or as clusters or components. In contrast, analysis of individual symptoms in either univariate or multivariate analysis did not reveal any associations, but HCA yielded a cluster that tended toward reduced risk of COVID-19 cases, and included patients that typically exhibited 3-5 symptoms, which were mainly fever, cough, headache, runny nose, or sore throat, few GIC, and lacking dyspnoea. Other PCA components tended toward associations in univariate analysis, although none was significant, nor were any significant in multivariate analysis. Nevertheless, the stronger tendency for associations of cluster and covariance constructs underscore the importance of interpreting infection as a systemic event.

Our results are in line with previous studies that identified older age, history of exposure, chronic underlying disease, symptoms, laboratory findings and chest x-ray examination. Specifically, we observed that persons ≥ 45 years had increased risk of infection, with 75% of confirmed cases being 45-65 years of age. This echoes previous reports wherein mean age of patients was over 40 years, and where critically ill patients were older than non-critical patients.(7) Liu W, et al., showed that age was significantly associated with the COVID-19 cases (OR, 10.6; 95% CI: 2.10–53.4; p value = 0.004) and disease progression (OR, 8.55; 95% CI: 1.63–44.8; P = 0.011) (8), similar to our study with aORs ranging from 5.32-9.01.

We also showed travel history increased the risk of COVID-19 cases with aORs 2.8 - 19.5, and with travel to Singapore or Malaysia being the most common endemic countries recently visited. This is supported by findings from Wells CR, et al. wherein the daily risk of exporting a confirmed case via international travel exceeded 95% by January 13, 2020 (9). They estimated that 64.3% of exported cases were pre-symptomatic while travelling. As expected, we observed that reported history of contact with a COVID-19 case was a very strong predictor of infection (OR 232; 95% CI 15.1-3569), similar to Liang W-hua, et al., where 1,334 of 1,590 (83.9%) had exposure history (10), and Wang R, et al. where 57.6% of patients had a history of exposure to persons from Wuhan within the past 2 weeks.(11) However, the association of recall of exposure with increased mortality was unanticipated, and warrants further exploration.

Our observation that pneumonia by chest x-ray strongly associated with infection with aORs 3.15 – 19.8 would be expected, and seen in previous report from Fuyang, China where 80% patients showed bilateral pneumonia by chest x-ray, and all of the critical patients showed pneumonia by x-ray.(11)

Similar to other findings, fever, cough and dyspnoea occurred in most patients, with cough and fever associated with infection, although not significant. Univariate regression with cluster analyses confirmed that patients with multiple symptoms, but without dyspnoea, were less likely to be infected (OR 0.04; 95% CI: <0.00-0.93; P= 0.037). This is consistent with reports that respiratory failure is associated with infection (OR, 8.021; 95% CI: 2.022-31.821; P = 0.003).(8)

The results on GIC warrant further study as angiotensin converting enzyme 2 (ACE-2), a virus receptor, is expressed in gastrointestinal epithelial cells. Viral nucleocapsid protein has also been identified in the gastric, duodenal, and rectum glandular epithelial cell cytoplasm. GI infection by SARS-CoV-2 may be important, and GI symptoms should not be overlooked among suspected cases.

We did not observe any significant associations of any laboratory results with infection or death. We note that a high neutrophil-to-lymphocyte ratio (NLR) with cut-off ≥ 3.13 was associated with a non-significant increased risk of infection. This cut-off value was based on previous studies which highlighted the importance of the NLR which reflects systemic inflammation.(7) Other than mortality, we did not explore the association of markers on with clinical severity of illness as evaluated in previous studies.

We found diabetes was a consistent and strong predictor for COVID-19 death.

Diabetes was previously reported as a risk factor for severe disease and mortality in SARS and MERS (Middle East respiratory syndrome) coronavirus infections, and H1N1 influenza.

A recent review summarized that diabetes increased the risk for SARS-CoV-2 infection and hospitalization, with a two-fold risk of severe disease or admission to the intensive care unit (ICU), and increased risk of death.(12) In our study 28% of COVID-19 patients had diabetes or hypertension. Others report increased comorbidity of cardiovascular, endocrine, and digestive disease, of which hypertension (30%) and diabetes (12.1%) were the most common.(13-16)

For death, we observed age ≥ 45 years tended toward an association but was not consistent across analyses. A study by Zhou, et al., showed that age is a predictor for mortality. (17) We also report no significant difference in the risk for infection or death based on sex. As mentioned, reported contact history was a predictor for mortality with aORs 51 − 144. One study of 3,019 suspected cases among health workers documented 1,716 confirmed cases with nearly 15% being severe and with 5 deaths. It was noted that transmission occurred mostly among close contacts.(18)

The underlying mechanism for how diabetes and older age are associated with adverse outcomes remains unclear, a current study of case series of COVID-19 patients demonstrated the potential contribution of pre-existing endothelial dysfunction. Post-mortem analysis of a renal transplant recipient aged 71 years whose condition deteriorated after

COVID-19 diagnosis showed structures of viral inclusion in endothelial cells and accumulation of endothelium-associated inflammatory cells. And post-mortem analysis of a 58-year diabetic woman revealed lymphocytic endotheliosis in lung, heart, kidney, and liver, in addition to evidence of myocardial infarction, but without signs of lymphocytic myocarditis. Endothelial cells express the ACE-2 virus receptor(19), and there may be increased expression of ACE-2 in the presence of comorbidities.(20-22) Hence, COVID-19 could cause widespread endothelial dysfunction from direct infection or immune-mediated recruitment of inflammatory cells, and provoke multiple organ failure. However, the relatively small size of our study precluded meaningful analysis of comorbidities.

Indonesia hosts many popular tourist destinations which created logistic, economic and political challenges to limiting foreign visitors. As part of the outbreak response, the Ministry of Health ordered the use of thermal scanners at ports of entry on 5 February 2020, prepared approximately 100 hospitals as COVID-19 referral hospitals, and assigned the National Institute for Health Research and Development to establish a coronavirus diagnostic laboratory supported by WHO and the USA Centers for Disease Control. The first two positive cases in Indonesia were announced by the President on 2 March 2020, but the actual number of cases remains unknown due to lack of active surveillance, lags in testing, and a testing strategy that limits assessment of patients with mild symptoms or persons asymptomatic for respiratory infection.

Indonesia now focuses on monitoring and preventing further spread by isolation, self-quarantine, and social distancing especially in large cities, such as Jakarta and Surabaya.(1, 23) The predictors in our study for increased risk of COVID-19 cases (age, international travel history, contact with a COVID-19 patient, pneumonia diagnosis by x-ray) and higher mortality (presence of diabetes and contact history), can be used as essential data for screening and surveillance, and help guide action to reduce transmission and mitigate effects from a possible second wave of COVID-19.

There are limitations to our study. First, the sample size was small as this is a preliminary study on COVID-19 during its emergence in Indonesia, and was limited to data that were accessible from that period. We also note the lack of data on smoking and body mass index. This is may be important because ACE-2 expression has been reported to increase in smokers and persons with complications of high body mass index.(24-26) Further investigation of correlates of expression, activation, and interaction of ACE-2 with SARS-CoV-2 in the Indonesian population would be important.

The likelihood of underreported cases needs to be considered given the variety of clinical manifestations and suboptimal availability of tools for diagnosis. Actions need to be taken such as a simulation to assess and verify pandemic preparedness for influx of cases at referral hospitals for proper triage, and establishment of high throughput diagnostics laboratories for COVID-19.

Conclusions

In independent and clustered variables analysis, older age, international travel history, contact with a COVID-19 patient, and pneumonia by x-ray were the predictors for increased risk of SARS-CoV-2 infection. The presence of diabetes and history of contact with COVID-19 cases were consistently associated with higher mortality. Association of individual symptoms with infection or mortality were not observed, whereas clustered symptoms or components tended to show stronger associations with infection. Use of such clusters in patient screening and assessment will be useful at the clinic and community level. The Ministry of Health needs to focus on preparedness measures, surveillance and public information to prevent movement of SARS-CoV-2 infection, and create messaging to alleviate public anxiety to enhance action and responsible behaviours.

36

List of abbreviations

ACE-2: angiotensin converting enzyme 2

COVID-19: Coronavirus disease 2019

CT: computed tomography

GIC: gastrointestinal complaints

HCA: hierarchical cluster analyses

IQR: interquartile range

NIHRD: National Institutes for Health Research and Development

NLR: neutrophil-to-lymphocyte ratio

PCA: principal component analyses

RT-PCR: real time polymerase chain reaction

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

SD: standard deviation

TB: lung tuberculosis

Declarations

Ethical approval and consent to participate

Ethical approval was obtained from the Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, with approval number 20030331. After consideration of ethical issues, logistics and urgency of this work, the Committee waived the requirement for written individual informed consent and approved the sharing of anonymized data.

37

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the

corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by grant award from the Directorate Research and Community

Services Universitas Indonesia (PUTI Q1) to AJR.

Authors' contributions

RA, AJR, AFS, DO, EB and AHS designed and coordinated this study. EB, RA, AG, KQP,

IGS, P, FI, DP, DL, NGL, VS and ADS collected the data. The data was analysed by RA and

interpreted by EB, RA, ISW, and AHS. EB, RA, AHS, ISW, AG, KQP and DR drafted the

manuscript together with the help of AJR. AHS provided feedback and helped streamline the

content and design analytical procedures. The corresponding author RA coordinated the final

38

submission of the paper. All authors contributed to the final version of the manuscript.

Acknowledgements

We thank Diah Handayani, Andriansjah Rukmana, Muhammad Luqman Labib Zufar,
Prasetio Adinugroho, and Annisa Feby Canintika for their insights and outstanding support in
drafting this study. We acknowledge the contributions from COVID-19 team of Persahabatan
Hospital, Sanglah Hospital, Gatot Subroto Central Army Hospital, and Raden Mattaher
Hospital to several authors and contributors to this work. This study was supported by the in
kind contributions of the Dean's Office and the Indonesian Medical Education and Research
Institute of the Faculty of Medicine Universitas Indonesia.

References

- 1. WHO. Update on coronavirus disease in Indonesia 2020 [Available from: https://www.who.int/indonesia/news/novel-coronavirus.
- 2. WHO . Coronavirus disease (COVID-19) Situation Dashboard 2020 [Available from: https://covid19.who.int/.
- 3. Liu S LH, Wang Y, Wang D, Ju S, Yang Y. Characteristics and Associations with Severity in COVID-19 Patients: A Multicentre Cohort Study from Jiangsu Province, China. SSRN Electron J. 2020.
- 4. Indonesia KKR. Pedoman Kesiapsiagaan Menghadapi Coronavirus Disease (COVID-19). 2020.
- 5. Indonesia KKR. Kesiapsiagaan COVID-19 di Indonesia 2020 [Available from: http://pusatkrisis.kemkes.go.id/kesiapsiagaan-covid-19-di-indonesia-per-tanggal-15-februari-2020.
- Prevention CfDCa. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. 2020.
- 7. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage 2020.
- 8. Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020.
- 9. Wells CR, Sah P, Moghadas SM, Pandey A, Shoukat A, Wang Y, et al. Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. Proc Natl Acad Sci U S A. 2020;117(13):7504-9.
- 10. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J. 2020.

- 11. Wang R, Pan M, Zhang X, Fan X, Han M, Zhao F, et al. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis. 2020.
- 12. Madsbad S. COVID-19 INFECTION IN PEOPLE WITH DIABETES2020. Available from: https://www.touchendocrinology.com/insight/covid-19-infection-in-people-with-diabetes/.
- 13. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020.
- 14. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.
- 15. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci. 2020;35(13):e142.
- 16. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142.
- 17. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-62.
- 18. M. ZWJ, McGoogan. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72.314 Cases From the Chinese Center for Disease Control and Prevention. 2020.
- 19. Lau SK, Woo PC, Yip CC, Tse H, Tsoi HW, Cheng VC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol. 2006;44(6):2063-71.
- 20. Oudit GY, Imai Y, Kuba K, Scholey JW, Penninger JM. The role of ACE2 in pulmonary diseases--relevance for the nephrologist. Nephrol Dial Transplant. 2009;24(5):1362-5.
- 21. Riviere G, Michaud A, Breton C, VanCamp G, Laborie C, Enache M, et al. Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. Hypertension. 2005;46(5):1169-74.
- 22. Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. Int J Mol Sci. 2017;18(3).
- 23. Jakarta GD. Instruksi Gubernur No. 23 Tahun 2020. 2020.
- 24. Cai G. 2020. Tobacco-use disparity in gene expression of ACE2, the receptor of 2019-nCov.
- 25. Wu C ZM. Single-cell RNA expression profiling shows that ACE2, the putative receptor of Wuhan has significant expression in the nasal, mouth ,lung and colon tissues, and tends to be co-expressed with HLA-DRB1 in the four tissues. 2020.
- 26. Zhao Y ZZ, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv. 2020.




Figure 1. Dendrogram of symptoms cluster for confirmed and suspected COVID-19

cases, and non-COVID-19 pneumonia patients